These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25038532)

  • 1. Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Marcus PM; Ogden SL; Gren LH; Childs JC; Pretzel SM; Lamerato LE; Walsh K; Rozjabek HM; Mabie J; Thomas B; Riley T
    Prev Med; 2014 Oct; 67():82-8. PubMed ID: 25038532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
    Pierre-Victor D; Pinsky PF
    JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Taylor KL; Shelby R; Gelmann E; McGuire C
    J Natl Cancer Inst; 2004 Jul; 96(14):1083-94. PubMed ID: 15265970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
    Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
    Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recruitment in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: the first phase of recruitment at Henry Ford Health System.
    Lamerato LE; Marcus PM; Jacobsen G; Johnson CC
    Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):827-33. PubMed ID: 18398023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Stallings FL; Ford ME; Simpson NK; Fouad M; Jernigan JC; Trauth JM; Miller DS;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):379S-389S. PubMed ID: 11189689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial.
    Trauth JM; Jernigan JC; Siminoff LA; Musa D; Neal-Ferguson D; Weissfeld J
    J Clin Oncol; 2005 Dec; 23(34):8730-8. PubMed ID: 16314633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Weissfeld JL; Fagerstrom RM; O'Brien B;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):390S-399S. PubMed ID: 11189690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
    Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
    Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
    Miller AB; Yurgalevitch S; Weissfeld JL;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):400S-406S. PubMed ID: 11189691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.
    Zhu CS; Pinsky PF; Kramer BS; Prorok PC; Purdue MP; Berg CD; Gohagan JK
    J Natl Cancer Inst; 2013 Nov; 105(22):1684-93. PubMed ID: 24115361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.
    Black A; Huang WY; Wright P; Riley T; Mabie J; Mathew S; Ragard L; Hermansen S; Yu K; Pinsky P; Prorok PC; Freedman ND; Hoover RN
    Rev Recent Clin Trials; 2015; 10(3):238-45. PubMed ID: 26435289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
    Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
    Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
    Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK;
    Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.